Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VTX002 versus placebo in moderately to severely active ulcerative colitis
2023-509233-39-00Phase 2Completed
- Sponsor
- Ventyx Biosciences
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 2, randomised, double-blind trial in autoimmune colitis comparing tamuzimod with placebo (2 arms). Primary endpoint: Clinical remission at Week 13. Started Sep 2024; status: completed.
02
Drugs
tamuzimod
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-509233-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509233-39-00.